NovaBridge Biosciences (NBP) Company presentation summary

Strategic vision and business model

• Focuses on bridging the gap between scientific innovation and patient impact by identifying, de-risking, and advancing high-potential therapies globally.

• Leverages privileged access, sophisticated development expertise, and disciplined capital allocation to create value.

• Applies a repeatable model across franchises, targeting unmet needs in oncology, ophthalmology, Europe, and women's health.

• Screens over 700 assets, with multiple programs under active evaluation and development.

Clinical pipeline and key assets

• Givastomig, a CLDN18.2-targeting therapy, advanced from Phase 1b to Phase 3 readiness in 18 months, showing a 77% confirmed ORR at 8 mg/kg in first-line gastroesophageal cancer.

• Givastomig has $5B+ peak sales potential across indications, with expansion into biliary tract and pancreatic cancers.

• VIS-101, a dual-targeting peptibody for ocular neovascularization, aims for best-in-class durability and less frequent dosing, with Phase 2b expected to start in 2H 2026.

• Ophthalmology franchise includes VIS-102 (term sheet signed for a rare disease biologic) and VIS-103 (under evaluation), targeting aggregate annual markets over $10B.

• Additional pipeline assets include ragistomig and uliledlimab in solid tumors and NSCLC, with ongoing and upcoming clinical milestones.

Financial position and growth outlook

• Maintains a debt-free balance sheet with approximately $210.8M in cash and equivalents as of December 31, 2025.

• Multiple value-creation pathways through development, partnering, financing, and affiliate formation.

• Plans to expand clinical and business development capabilities, scale asset sourcing, and achieve sustainable profitability over the next 5–10 years.

• Partnership and financing discussions ongoing for key franchises and new growth platforms.